Because ANA titers were measured at baseline, before initiation of any biologic or immunomodulator therapy, the observed ANA positivity in this Taiwanese IBD cohort likely reflects pre-existing autoimmunity rather than drug-induced autoantibody formation and thus occurred independently of TNFi exposure. Here, BTG3 is linked to inflammatory bowel disease.